Intraoperative Ultrasound-Guided Cryoablation of Renal Tumors

Publication
Article
OncologyONCOLOGY Vol 12 No 11
Volume 12
Issue 11

Renal cancer occurs in nearly 10 of every 100,000 people in the United States and in approximately 45 of every 100,000 of those over 65 years of age. Standard treatment is open surgery, often involving total removal of the tumor along with the kidney. However, a study in the September issue of the Journal of Ultrasound in Medicine reports that ultrasound-guided renal cryoablation is a feasible technique for treating renal malignancies while still preserving the renal parenchyma.

Renal cancer occurs in nearly 10 of every 100,000 people in the United States and in approximately 45 of every 100,000 of those over 65 years of age. Standard treatment is open surgery, often involving total removal of the tumor along with the kidney. However, a study in the September issue of the Journal of Ultrasound in Medicine reports that ultrasound-guided renal cryoablation is a feasible technique for treating renal malignancies while still preserving the renal parenchyma.

Sparing Renal Tissue

Harry G. Zegel, MD, and coauthors from theAllegheny University Hospitals in Pennsylvania and Urology Specialists of Coastal Georgia write, "Recent advances in cross-sectional imaging (ultrasound, MRI, CT) have led to increased detection of small, asymptomatic renal tumors. Also, in selected cases, patients undergoing partial nephrectomy have been reported to have rates of survival similar to those of patients undergoing radical nephrectomy. This has led some physicians to question the need for radical nephrectomy in patients with small lesions. While partial nephrectomy spares the maximal amount of functioning renal tissue, and often eliminates or postpones the need for dialysis, this technique is associated with risks. Hence, better kidney tissue-sparing techniques may be of benefit in selected patients."

The study examined the feasibility of using ultrasound-guided cryosurgery to treat selected patients with renal malignancy by studying the technique in six patients with renal tumors.

Benefits of Intraoperative Ultrasonography

In the study, intraoperative ultrasonography accurately delineated tumor size, cryoprobe placement, and depth of freezing in all patients. In addition, intraoperative ultrasonography identified a total of nine additional lesions in three patients that had not been detected by preoperative imaging. The patients have been followed with clinical and laboratory assessments, as well as MRI or CT imaging, and all were tumor-free 3 to 22 months, postoperatively.

In conclusion, the authors write, "we conclude that cryoablation with intraoperative ultrasonographic guidance is a promising new technique for treating renal masses while preserving renal parenchyma and function. Long-term follow-up in a larger series of patients with biopsy-proved lesions is necessary to determine the true efficacy and safety of this procedure."

Recent Videos
An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
Kidney cancer advocacy efforts have spread the urgency and importance of funding research in the field to members of Congress.
Advocacy efforts have yielded a dramatic increase in kidney cancer research, according to Elizabeth P. Henske, MD.
A review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.
A phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
Analysis of 2 phase 1 trials compared gut biome diversity between standard of care with or without CBM588 in patients with metastatic renal cell carcinoma.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Related Content